A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants
Completed · Phase 1
Conditions studied: Healthy Volunteers
In brief
The purpose of this study is to characterize the effect of itraconazole (Part 1) and rifampin (Part 2) on the single-dose pharmacokinetics (PK) of TAK-788 and its active metabolites (AP32960 and AP32914) in healthy adult participants.
Key facts
- Study ID
- NCT03928327
- Run by
- Millennium Pharmaceuticals, Inc.
- People needed
- 24
- Starts
- 2019-05-02
- Expected to finish
- 2019-08-16
- Last updated by the study team
- 2020-08-21
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Celerion — Tempe, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.